喹硫平治疗老年痴呆患者精神行为症状的临床观察

摘要

目的 观察喹硫平与奋乃静对老年痴呆患者的疗效和安全性.方法 将52例老年痴呆患者随机分成两组:研究组给予喹硫平治疗,剂量范围为50～400 mg/d(26例);对照组给予奋乃静治疗,剂量范围为6～16 mg/d(26例),观察8周.采用简易智力状态检查(MMSE)、老年临床评定量表(SCAG)、副反应量表(TESS)分别于入组前和入组第8周末时进行评定,比较两组的疗效和安全性.结果 治疗结束时,两组较入组时MMSE评分均非常显著增高(P<0.01)、SCAG评分均显著减低(P<0.01或0.05);研究组和对照组的不良反应发生率分别为为30.8%和46.2%,研究组明显低于对照组(P<0.05).结论 喹硫平治疗老年痴呆的疗效好,不良反应少,适合临床应用.%Objective To explore the efficacy and safety of quetiapine and perphenazine in the treatment of Alzheimer's disease. Metbods 52 patients were randomly assigned to receive quetiapine of SO - 400mg daily ( 26 patients, study group), or perphenazine of 6-16mg daily ( 26 patients, control group )for 8 weeks. The efficacy and safety of the two therapies was compared between the two groups by using the Mini-mental State Examination ( MMSE ), Sandoz Clincal Assessment Geriatric ( SCAG ), and Treatment Emergent Symptom Scale (TESS ) 8 weeks after treatment. Results At the completion of treatment, the scores on MMSE were significantly higher ( P< 0.01 ), and those on SCAG were significantly lower in both groups ( P< 0.01 or P< 0.05 ), as compared with the baseline scores. The rate of adverse reactions was significantly lower in the study group than in the control group ( 30.8% vs. 46.2%, P< 0.05 ) Conclusions Quetiapine has a better efficacy in the treatment of Alzheimer's disease and has fewer adverse reactions. It is suitable for clinical use.